0001179110-17-012517.txt : 20170920 0001179110-17-012517.hdr.sgml : 20170920 20170920173733 ACCESSION NUMBER: 0001179110-17-012517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170918 FILED AS OF DATE: 20170920 DATE AS OF CHANGE: 20170920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LYNCH DANIEL CENTRAL INDEX KEY: 0001177082 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37359 FILM NUMBER: 171094693 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Blueprint Medicines Corp CENTRAL INDEX KEY: 0001597264 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-374-7580 MAIL ADDRESS: STREET 1: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2017-09-18 0 0001597264 Blueprint Medicines Corp BPMC 0001177082 LYNCH DANIEL C/O BLUEPRINT MEDICINES CORPORATION 38 SIDNEY STREET, SUITE 200 CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2017-09-18 4 S 0 2500 60.00 D 209342 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. /s/ Christopher Frankenfield, Attorney-in-Fact 2017-09-18